Clinical trials: Etoposide, completed
Lung Cancer
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003158
- Testing
- carboplatin, etoposide, paclitaxel
- Where
- 86 sites in United States
- Volunteers
- 96 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00006122
- Testing
- cytarabine, etoposide, gemtuzumab ozogamicin
- Where
- 18 sites in Austria, Belgium and 5 more
- Volunteers
- 106 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hodgkin Lymphoma, Lymphoma
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
Primary Objectives: 1. To determine the toxicity profile of multiple doses of bortezomib when given with ICE in patients with relapsed and refractory classical Hodgkin lymphoma (HL). 2.
- Trial name
- NCT00439361
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Neutropenia
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00002719
- Testing
- filgrastim, amsacrine, carmustine
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004169
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Hodgkin´s Lymphoma
HD12 for Advanced Stages
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
- Trial name
- NCT00265031
- Testing
- Cyclophosphamide, Adriamycin, Etoposide
- Sponsor
- University of Cologne
Leukemia, Lymphoma
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004898
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Leukemia, Myelodysplastic Syndromes
Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing and die. Bone marrow transplantation may be able to replace cells that were destroyed by chemotherapy.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00004899
- Testing
- filgrastim, busulfan, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004907
- Testing
- busulfan, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058292
- Testing
- filgrastim, rituximab, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells.
- Trial name
- NCT00003215
- Testing
- filgrastim, CHOP regimen, cyclophosphamide
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 400 people
- Sponsor
- Swiss Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00573690
- Testing
- carboplatin, cisplatin, etoposide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Leukemia
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002945
- Testing
- aldesleukin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as carboplatin and etoposide use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061919
- Testing
- Carboplatin, etoposide & thalidomide
- Where
- United Kingdom
- Volunteers
- 724 people
- Sponsor
- University College, London
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Lymphoma
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00018954
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 5 sites in United States, Egypt and 1 more
- Sponsor
- National Institutes of Health Clinical Center (CC)
Prostate Cancer
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate cancer and neuro-endocrine differentiation.
- Trial name
- NCT00973882
- Testing
- Carboplatin, Etoposide
- Where
- 11 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Retinoblastoma
Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004006
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Ovarian Cancer
Clinical Benefit of Topoisomerase Downregulation
1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16) 1.2 To determine the time to progression and the objective response rate of this treatment in…
- Trial name
- NCT00250094
- Testing
- Topotecan and VP16
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance